BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 132 filers reported holding BRIDGEBIO PHARMA INC in Q3 2020. The put-call ratio across all filers is 0.69 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,129,648 | +4148.6% | 308,292 | +2671.2% | 0.01% | – |
| Q2 2023 | $191,350 | +2.9% | 11,125 | +2.6% | 0.00% | – |
| Q1 2023 | $185,992 | +122.5% | 10,845 | -1.1% | 0.00% | – |
| Q4 2022 | $83,591 | -97.5% | 10,970 | -96.7% | 0.00% | -100.0% |
| Q3 2022 | $3,344,000 | +10.5% | 336,426 | +0.9% | 0.00% | +50.0% |
| Q2 2022 | $3,027,000 | -11.4% | 333,368 | -0.9% | 0.00% | 0.0% |
| Q1 2022 | $3,416,000 | -0.6% | 336,532 | +63.3% | 0.00% | 0.0% |
| Q4 2021 | $3,437,000 | -71.7% | 206,067 | -20.6% | 0.00% | -75.0% |
| Q3 2021 | $12,159,000 | -23.2% | 259,416 | -0.2% | 0.01% | -27.3% |
| Q2 2021 | $15,839,000 | +3.3% | 259,824 | +4.4% | 0.01% | 0.0% |
| Q1 2021 | $15,326,000 | -14.8% | 248,798 | -1.6% | 0.01% | -21.4% |
| Q4 2020 | $17,981,000 | +114.9% | 252,865 | +13.4% | 0.01% | +100.0% |
| Q3 2020 | $8,366,000 | +30.7% | 222,967 | +13.6% | 0.01% | +16.7% |
| Q2 2020 | $6,399,000 | – | 196,241 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |